Dianthus Therapeutics (DNTH) Preferred Dividend Payments (2017 - 2018)
Dianthus Therapeutics' (DNTH) quarterly Preferred Dividend Payments came in at $88000.0 in Q2 2018, down 57.49% year-on-year from $207000.0 in Q2 2017, and up 1366.67% quarter-over-quarter from $6000.0 in Q3 2017.
Dianthus Therapeutics (DNTH) Preferred Dividend Payments (2017 - 2018) Analysis & Trends
Dianthus Therapeutics' Preferred Dividend Payments history runs 2 years deep, the most recent figure standing at $88000.0 for Q2 2018.
- On a quarterly basis, Preferred Dividend Payments fell 57.49% year-over-year to $88000.0 in Q2 2018; TTM through Dec 2018 was $88000.0, a N/A change from a year earlier, with the FY2018 full-year figure at $88000.0, down 79.86% from the prior year.
- Preferred Dividend Payments advanced to $88000.0 in Q2 2018 per DNTH's latest filing, from $6000.0 in the prior quarter.
- Across five years, Preferred Dividend Payments topped out at $207000.0 in Q2 2017 and bottomed at $6000.0 in Q3 2017.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Pref Dividends (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | Dianthus Therapeutics | 3.92 Bn | 3.51 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2018 | 88,000.00 |
| Sep 30, 2017 | 6,000.00 |
| Jun 30, 2017 | 207,000.00 |